Combined treatment of malignant salivary gland tumours with intensity-modulated radiation therapy (IMRT) and carbon ions: COSMIC

<p>Abstract</p> <p>Background</p> <p>Local control in malignant salivary gland tumours is dose dependent. High local control rates in adenoid cystic carcinomas could be achieved by highly conformal radiotherapy techniques and particle (neutron/carbon ion) therapy. Consi...

Full description

Bibliographic Details
Main Authors: Windemuth-Kieselbach Christine, Nikoghosyan Anna, Jensen Alexandra D, Debus Jürgen, Münter Marc W
Format: Article
Language:English
Published: BMC 2010-10-01
Series:BMC Cancer
Online Access:http://www.biomedcentral.com/1471-2407/10/546
id doaj-39fc521f528d4b60821d871f7bf528be
record_format Article
spelling doaj-39fc521f528d4b60821d871f7bf528be2020-11-24T20:51:30ZengBMCBMC Cancer1471-24072010-10-0110154610.1186/1471-2407-10-546Combined treatment of malignant salivary gland tumours with intensity-modulated radiation therapy (IMRT) and carbon ions: COSMICWindemuth-Kieselbach ChristineNikoghosyan AnnaJensen Alexandra DDebus JürgenMünter Marc W<p>Abstract</p> <p>Background</p> <p>Local control in malignant salivary gland tumours is dose dependent. High local control rates in adenoid cystic carcinomas could be achieved by highly conformal radiotherapy techniques and particle (neutron/carbon ion) therapy. Considering high doses are needed to achieve local control, all malignant salivary gland tumours probably profit from the use of particle therapy, which in case of carbon ion treatment, has been shown to be accompanied by only mild side-effects.</p> <p>Methods/design</p> <p>The COSMIC trial is a prospective, mono-centric, phase II trial evaluating toxicity (primary endpoint: mucositis ≥ CTCAE°3) and efficacy (secondary endpoint: local control, disease-free survival) in the combined treatment with IMRT and carbon ion boost in 54 patients with histologically proved (≥R1-resected, inoperable or Pn+) salivary gland malignancies. Patients receive 24 GyE carbon ions (8 fractions) and IMRT (50 Gy at 2.0 Gy/fraction).</p> <p>Discussion</p> <p>The primary objective of COSMIC is to evaluate toxicity and feasibility of the proposed treatment in all salivary gland malignancies.</p> <p>Trial Registration</p> <p>Clinical trial identifier NCT 01154270</p> http://www.biomedcentral.com/1471-2407/10/546
collection DOAJ
language English
format Article
sources DOAJ
author Windemuth-Kieselbach Christine
Nikoghosyan Anna
Jensen Alexandra D
Debus Jürgen
Münter Marc W
spellingShingle Windemuth-Kieselbach Christine
Nikoghosyan Anna
Jensen Alexandra D
Debus Jürgen
Münter Marc W
Combined treatment of malignant salivary gland tumours with intensity-modulated radiation therapy (IMRT) and carbon ions: COSMIC
BMC Cancer
author_facet Windemuth-Kieselbach Christine
Nikoghosyan Anna
Jensen Alexandra D
Debus Jürgen
Münter Marc W
author_sort Windemuth-Kieselbach Christine
title Combined treatment of malignant salivary gland tumours with intensity-modulated radiation therapy (IMRT) and carbon ions: COSMIC
title_short Combined treatment of malignant salivary gland tumours with intensity-modulated radiation therapy (IMRT) and carbon ions: COSMIC
title_full Combined treatment of malignant salivary gland tumours with intensity-modulated radiation therapy (IMRT) and carbon ions: COSMIC
title_fullStr Combined treatment of malignant salivary gland tumours with intensity-modulated radiation therapy (IMRT) and carbon ions: COSMIC
title_full_unstemmed Combined treatment of malignant salivary gland tumours with intensity-modulated radiation therapy (IMRT) and carbon ions: COSMIC
title_sort combined treatment of malignant salivary gland tumours with intensity-modulated radiation therapy (imrt) and carbon ions: cosmic
publisher BMC
series BMC Cancer
issn 1471-2407
publishDate 2010-10-01
description <p>Abstract</p> <p>Background</p> <p>Local control in malignant salivary gland tumours is dose dependent. High local control rates in adenoid cystic carcinomas could be achieved by highly conformal radiotherapy techniques and particle (neutron/carbon ion) therapy. Considering high doses are needed to achieve local control, all malignant salivary gland tumours probably profit from the use of particle therapy, which in case of carbon ion treatment, has been shown to be accompanied by only mild side-effects.</p> <p>Methods/design</p> <p>The COSMIC trial is a prospective, mono-centric, phase II trial evaluating toxicity (primary endpoint: mucositis ≥ CTCAE°3) and efficacy (secondary endpoint: local control, disease-free survival) in the combined treatment with IMRT and carbon ion boost in 54 patients with histologically proved (≥R1-resected, inoperable or Pn+) salivary gland malignancies. Patients receive 24 GyE carbon ions (8 fractions) and IMRT (50 Gy at 2.0 Gy/fraction).</p> <p>Discussion</p> <p>The primary objective of COSMIC is to evaluate toxicity and feasibility of the proposed treatment in all salivary gland malignancies.</p> <p>Trial Registration</p> <p>Clinical trial identifier NCT 01154270</p>
url http://www.biomedcentral.com/1471-2407/10/546
work_keys_str_mv AT windemuthkieselbachchristine combinedtreatmentofmalignantsalivaryglandtumourswithintensitymodulatedradiationtherapyimrtandcarbonionscosmic
AT nikoghosyananna combinedtreatmentofmalignantsalivaryglandtumourswithintensitymodulatedradiationtherapyimrtandcarbonionscosmic
AT jensenalexandrad combinedtreatmentofmalignantsalivaryglandtumourswithintensitymodulatedradiationtherapyimrtandcarbonionscosmic
AT debusjurgen combinedtreatmentofmalignantsalivaryglandtumourswithintensitymodulatedradiationtherapyimrtandcarbonionscosmic
AT muntermarcw combinedtreatmentofmalignantsalivaryglandtumourswithintensitymodulatedradiationtherapyimrtandcarbonionscosmic
_version_ 1716802084870815744